Evaluation of the Ki-67 labeling index on immediate pre-ablation biopsies as a predictive biomarker of local recurrence of colorectal cancer liver metastases Journal Article

   

Authors:	Sotirchos, V. S.; Vakiani, E.; Sigel, C.; Imam, R.; Kunin, H. S.; Cooke, T. M.; Gönen, M.; Solomon, S. B.; Erinjeri, J. P.; Sofocleous, C. T.
Article Title:	Evaluation of the Ki-67 labeling index on immediate pre-ablation biopsies as a predictive biomarker of local recurrence of colorectal cancer liver metastases
Abstract:	The aim of this study was to evaluate if the Ki-67 labeling index (LI) on immediate pre-ablation biopsies of colorectal liver metastases (CLM) is associated with the presence of viable tumor cells in subsequent ablation zone biopsies and/or local tumor progression-free survival (LTPFS). Biopsies of CLM were performed before and after microwave ablation (MWA), as part of a prospective clinical trial between October 2013 and May 2019. Pre-ablation biopsy slides were examined for the Ki-67 LI using light microscopy. Ablation zone biopsy specimens were evaluated for the presence of viable tumor using hematoxylin–eosin and immunohistochemistry. Differences in CLM Ki-67 LI between positive and negative for viable tumor ablation zone biopsies were assessed using the Mann–Whitney U test. Biopsy, tumor and margin data were evaluated as predictors of LTPFS using Kaplan–Meier/Cox methods. Thirty-four patients with 48 CLM underwent biopsy before and after MWA. Sufficient tissue for Ki-67 labeling was obtained in 43/48 (89.6%) CLM. Viable tumor cells were detected in 11 ablation zones (22.9%). There was no significant difference in the CLM Ki-67 LI between the positive and negative for viable tumor ablation zones (mean: 69.2% vs. 64.3% respectively, p = 0.4). Adequate ablation zone margins (> 5 mm; p = 0.029) and negative ablation zone biopsies (p = 0.009) were significant predictors of longer LTPFS. KRAS status, tumor size and Ki-67 LI were not significant predictors of LTPFS. Complete tumor ablation (with adequate margins and negative ablation zone biopsies) is the most important factor in achieving local control of CLM, even for tumors exhibiting aggressive tumor biology. © The Author(s), under exclusive licence to Springer Nature B.V. 2024.
Keywords:	immunohistochemistry; adult; cancer chemotherapy; cancer survival; clinical article; controlled study; human tissue; aged; cancer recurrence; nuclear magnetic resonance imaging; follow up; antineoplastic agent; ki 67 antigen; biomarkers; progression free survival; tumor volume; biopsy; liver metastasis; recurrent disease; hepatectomy; floxuridine; liver biopsy; labeling index; fluoroscopy; surgical margin; genotyping; ablation; tumor ablation; microwave ablation; local tumor progression; high throughput sequencing; proliferation index; colorectal liver metastasis; human; male; female; article; positron emission tomography-computed tomography; microwave thermotherapy; light microscopy; pre ablations; labelings; liver biopsies; local tumor progressions; tumour ablation
Journal Title:	Cytotechnology
Volume:	77
ISSN:	0920-9069
Publisher:	Springer
Date Published:	2025-01-01
Start Page:	31
Language:	English
DOI:	10.1007/s10616-024-00700-8
PROVIDER:	scopus
PMCID:	PMC11685365
PUBMED:	39744311
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85213692433&doi=10.1007%2fs10616-024-00700-8&partnerID=40&md5=f71e22899ee44989df69b238b209f7ce
Notes:	The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: Vlasios S. Sotirchos -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/222163